Global Non-invasive Cancer Diagnosis Market Research and Forecast 2017-2022
The Global Non-invasive cancer diagnosis Market is expected to grow at the CAGR of 7.2% during 2017-2022. Rising chronic cancers with a growing demand of minimally invasive diagnosis are driving the non-invasive cancer diagnosis market across the globe. Non-invasive cancer diagnostic is an approach used for detection of the cancer conditions with minimal incision in body during diagnosis. According to WHO, 14 million cases of cancer were reported and 8.2 million died in 2012. The numbers of fatalities have been increased to 8.8 million during 2015-16. This significant number of cancer cases has shifted the global attention towards the adoption of early detection and diagnosis techniques for cancer. Additionally, the growing awareness programs and initiatives by government and healthcare organizations are boosting the market growth across the globe. Cancer Research UK, the Department of Health, NHS England and Public Health England in collaboration has launched National Awareness and Early Diagnosis Initiative (NAEDI). The initiative aims to increase awareness of the signs and symptoms of cancer amongst the general public and medical professionals, and to promote early diagnosis. Many more number of such initiatives are creating awareness among global patients for diagnosis and treatment of cancer.
However, high costs of these diagnosis techniques are the major factor hindering the market growth. The government stringent regulations for these techniques are somehow restraints of this market. FDA, Medicare and Medicaid Services (CMS) and Social Security Administration (SSA) have issued ovarian cancer national alliance regulations for regulating non-invasive monitoring devices. Additionally, R&D works in cancer research and its diagnosis along with some technological innovations in techniques are expected in the upcoming years. Liquid biopsy has emerged an innovative and promising non-invasive cancer diagnostic tool for early detection as well as monitoring the disease’s progress in the recent years.
Geographical Insights
At present, North America holds the highest market share of the Non-Invasive Cancer diagnosis market. High awareness in people towards early diagnosis for cancer and well structured reimbursement policies in the region are driving the market. Additionally, the affordability to these high cost techniques is a major factor for this growth. However, Asia Pacific region is the fastest growing region during the forecasted period. The large populated countries such as China and India are supposed to be getting more awareness about the cancer diseases and non-invasive techniques to diagnose them. This would drive the market growth in that region.
Competitive Insights
Some of the key players contributing in the growth of global non invasive cancer diagnostics market include Gen-Probe Inc., A&G Pharmaceutical, Affymetrix Inc., Digene Corporation, Quest Diagnostics Inc., BioView Inc., LabCorp, AVIVA Biosciences Corporation and Precision Therapeutics. Non-invasive cancer diagnostics market companies are constantly focusing on product launch, R&D, partnerships, M&A, innovation and technological advancement. The report also includes detailed market overview, strategic recommendations, key company analysis, key findings, analyst insights, predictive analysis, market determinants, market segmentation, geographical analysis, company profiling of the market.
Market Segmentation
Global Non-Invasive cancer market can be segmented on the basis of their techniques and Cancer types. There are various techniques such as molecular diagnosis, clinical chemistry and so on. While, the cancer type segment is bifurcated into lung cancer, solid tumors, breast cancer and so on. Breast cancer and molecular diagnosis holds the largest market share in the non-invasive cancer diagnosis market. Global Non-Invasive Cancer Diagnosis market is bifurcated as follows:
Global Non-Invasive cancer diagnosis Market Research and Analysis, by Type
Global Non-Invasive cancer diagnosis Market Research and Analysis, by Techniques
The report covers
However, high costs of these diagnosis techniques are the major factor hindering the market growth. The government stringent regulations for these techniques are somehow restraints of this market. FDA, Medicare and Medicaid Services (CMS) and Social Security Administration (SSA) have issued ovarian cancer national alliance regulations for regulating non-invasive monitoring devices. Additionally, R&D works in cancer research and its diagnosis along with some technological innovations in techniques are expected in the upcoming years. Liquid biopsy has emerged an innovative and promising non-invasive cancer diagnostic tool for early detection as well as monitoring the disease’s progress in the recent years.
Geographical Insights
At present, North America holds the highest market share of the Non-Invasive Cancer diagnosis market. High awareness in people towards early diagnosis for cancer and well structured reimbursement policies in the region are driving the market. Additionally, the affordability to these high cost techniques is a major factor for this growth. However, Asia Pacific region is the fastest growing region during the forecasted period. The large populated countries such as China and India are supposed to be getting more awareness about the cancer diseases and non-invasive techniques to diagnose them. This would drive the market growth in that region.
Competitive Insights
Some of the key players contributing in the growth of global non invasive cancer diagnostics market include Gen-Probe Inc., A&G Pharmaceutical, Affymetrix Inc., Digene Corporation, Quest Diagnostics Inc., BioView Inc., LabCorp, AVIVA Biosciences Corporation and Precision Therapeutics. Non-invasive cancer diagnostics market companies are constantly focusing on product launch, R&D, partnerships, M&A, innovation and technological advancement. The report also includes detailed market overview, strategic recommendations, key company analysis, key findings, analyst insights, predictive analysis, market determinants, market segmentation, geographical analysis, company profiling of the market.
Market Segmentation
Global Non-Invasive cancer market can be segmented on the basis of their techniques and Cancer types. There are various techniques such as molecular diagnosis, clinical chemistry and so on. While, the cancer type segment is bifurcated into lung cancer, solid tumors, breast cancer and so on. Breast cancer and molecular diagnosis holds the largest market share in the non-invasive cancer diagnosis market. Global Non-Invasive Cancer Diagnosis market is bifurcated as follows:
Global Non-Invasive cancer diagnosis Market Research and Analysis, by Type
Global Non-Invasive cancer diagnosis Market Research and Analysis, by Techniques
The report covers
- Comprehensive research methodology of Global Non-Invasive cancer diagnosis Market.
- This report also includes detailed and extensive market overview with current market recommendations & key analysts insights.
- Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the Global Non-Invasive cancer diagnosis Market.
- Insights about market determinants which are stimulating the Global Non-Invasive cancer diagnosis Market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST INSIGHT&CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. REGULATIONS
2.3.1. UNITED STATES
2.3.2. EUROPEAN UNION
2.3.3. CHINA
2.3.4. INDIA
2.3.5. REST OF THE WORLD
2.4. PATENT ANALYSIS
MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. INCREASE IN INCIDENCE AND PREVALENCE RATE OF CHRONIC CANCER
3.1.2. MINIMALLY INVASIVE THERAPEUTICS
3.1.3. GROWTH IN PRIVATE DIAGNOSTIC CENTERS
3.1.4. INCREASING AWARENESS TOWARDS CANCER
3.1.5. GOVERNMENT INITIATIVES TOWARDS CANCER DIAGNOSIS
3.2. RESTRAINTS
3.2.1. HIGH COSTS OF DIAGNOSIS
3.2.2. STRICT GOVERNMENT REGULATIONS
3.3. OPPORTUNITIES
3.3.1. TECHNOLOGICAL ADVANCEMENTS
3.3.2. RESEARCH & DEVELOPMENT WORK IN CANCER DIAGNOSIS
3.3.3. INCREASE IN REIMBURSEMENT POLICIES FOR CANCER
MARKET SEGMENTATION
4.1. NON-INVASIVE CANCER DIAGNOSIS MARKET BY TYPE
4.1.1. BLOOD CANCER
4.1.2. SOLID TUMORS
4.1.3. BREAST CANCER
4.1.4. LUNG CANCER
4.1.5. OTHERS
4.2. NON-INVASIVE CANCER DIAGNOSIS MARKET BY TECHNIQUES
4.2.1. CLINICAL CHEMISTRY
4.2.2. IMMUNOCHEMISTRY/IMMUNOASSAY
4.2.3. MOLECULAR DIAGNOSTICS
4.2.4. OTHER CLINICAL INSTRUMENTS
COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.2. KEY COMPANY ANALYSIS
REGIONAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. UNITED STATES
6.1.2. CANADA
6.1.3. REST OF NORTH AMERICA
6.2. EUROPE
6.2.1. UNITED KINGDOM
6.2.2. FRANCE
6.2.3. GERMANY
6.2.4. ITALY
6.2.5. SPAIN
6.2.6. REST OF EUROPE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.4. REST OF THE WORLD
COMPANY PROFILES
7.1. A&G PHARMACEUTICAL, INC.
7.1.1. INTRODUCTION
7.1.2. A7G PHARMACEUTICAL PRODUCT PORTFOLIO
7.1.3. A&G PHARMACEUTICAL RECENT ACTIVITIES
7.2. ACCELERATE BRAIN CANCER CURE
7.2.1. INTRODUCTION
7.2.2. ACCELERATE BRAIN CANCER CURE PRODUCT PORTFOLIO
7.2.3. ACCELERATE BRAIN CANCER CURE RECENT ACTIVITIES
7.3. ADMERA HEALTH INNOVATIONS
7.3.1. INTRODUCTION
7.3.2. ADMERA HEALTH INNOVATIONS PRODUCT PORTFOLIO
7.3.3. ADMERA HEALTH INNOVATIONS RECENT ACTIVITIES
7.4. AFFYMETRIX INC.
7.4.1. INTRODUCTION
7.4.2. AFFYMETRIX INC. PRODUCT PORTFOLIO
7.4.3. AFFYMETRIX INC. RECENT ACTIVITIES
7.5. AVIVA BIOSCIENCES CORPORATION
7.5.1. INTRODUCTION
7.5.2. AVIVA BIOSCIENCES CORPORATION PRODUCT PORTFOLIO
7.5.3. AVIVA BIOSCIENCES CORPORATION RECENT ACTIVITIES
7.6. BIOVIEW INC.
7.6.1. INTRODUCTION
7.6.2. BIOVIEW INC. PRODUCT PORTFOLIO
7.6.3. BIOVIEW INC. RECENT ACTIVITIES
7.7. CYNVENIO BIOSYSTEMS
7.7.1. INTRODUCTION
7.7.2. CYNVENIO BIOSYSTEMS PRODUCT PORTFOLIO
7.7.3. CYNVENIO BIOSYSTEMS RECENT ACTIVITIES
7.8. DIGENE CORPORATION
7.8.1. INTRODUCTION
7.8.2. DIGENE CORPORATION PRODUCT PORTFOLIO
7.8.3. DIGENE CORPORATION RECENT ACTIVITIES
7.9. EXOSOMICS SIENA
7.9.1. INTRODUCTION
7.9.2. EXOSOMICS SIENA PRODUCT PORTFOLIO
7.9.3. EXOSOMICS SIENA RECENT ACTIVITIES
7.10. FLARITON HEALTH
7.10.1. INTRODUCTION
7.10.2. FLARITON HEALTH PRODUCT PORTFOLIO
7.10.3. FLARITON HEALTH RECENT ACTIVITIES
7.11. GEN-PROBE INCORPORATED
7.11.1. INTRODUCTION
7.11.2. GEN-PROBE INCORPORATED PRODUCT PORTFOLIO
7.11.3. GEN-PROBE INCORPORATED RECENT ACTIVITIES
7.12. IV DIAGNOSTICS, INC.
7.12.1. INTRODUCTION
7.12.2. IV DIAGNOSTICS, INC. PRODUCT PORTFOLIO
7.12.3. IV DIAGNOSTICS, INC. RECENT ACTIVITIES
7.13. LABCORP
7.13.1. INTRODUCTION
7.13.2. LABCORP PRODUCT PORTFOLIO
7.13.3. LABCORP RECENT ACTIVITIES
7.14. NEOGENOMICS
7.14.1. INTRODUCTION
7.14.2. NEOGENOMICS PRODUCT PORTFOLIO
7.14.3. NEOGENOMICS RECENT ACTIVITIES
7.15. NOVARTIS
7.15.1. INTRODUCTION
7.15.2. NOVARTIS PRODUCT PORTFOLIO
7.15.3. NOVARTIS RECENT ACTIVITIES
7.16. NOVIGENIX
7.16.1. INTRODUCTION
7.16.2. NOVIGENIX PRODUCT PORTFOLIO
7.16.3. NOVIGENIX RECENT ACTIVITIES
7.17. PRECISION THERAPEUTICS, INC.
7.17.1. INTRODUCTION
7.17.2. PRECISION THERAPEUTICS, INC.PRODUCT PORTFOLIO
7.17.3. PRECISION THERAPEUTICS, INC. RECENT ACTIVITIES
7.18. QIAGEN
7.18.1. INTRODUCTION
7.18.2. QIAGENPRODUCT PORTFOLIO
7.18.3. QIAGENRECENT ACTIVITIES
7.19. QUANTERIX
7.19.1. INTRODUCTION
7.19.2. QUANTERIX PRODUCT PORTFOLIO
7.19.3. QUANTERIX RECENT ACTIVITIES
7.20. QUEST DIAGNOSTICS INC.,
7.20.1. INTRODUCTION
7.20.2. QUEST DIAGNOSTICS INC., PRODUCT PORTFOLIO
7.20.3. QUEST DIAGNOSTICS INC., RECENT ACTIVITIES
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST INSIGHT&CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. REGULATIONS
2.3.1. UNITED STATES
2.3.2. EUROPEAN UNION
2.3.3. CHINA
2.3.4. INDIA
2.3.5. REST OF THE WORLD
2.4. PATENT ANALYSIS
MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. INCREASE IN INCIDENCE AND PREVALENCE RATE OF CHRONIC CANCER
3.1.2. MINIMALLY INVASIVE THERAPEUTICS
3.1.3. GROWTH IN PRIVATE DIAGNOSTIC CENTERS
3.1.4. INCREASING AWARENESS TOWARDS CANCER
3.1.5. GOVERNMENT INITIATIVES TOWARDS CANCER DIAGNOSIS
3.2. RESTRAINTS
3.2.1. HIGH COSTS OF DIAGNOSIS
3.2.2. STRICT GOVERNMENT REGULATIONS
3.3. OPPORTUNITIES
3.3.1. TECHNOLOGICAL ADVANCEMENTS
3.3.2. RESEARCH & DEVELOPMENT WORK IN CANCER DIAGNOSIS
3.3.3. INCREASE IN REIMBURSEMENT POLICIES FOR CANCER
MARKET SEGMENTATION
4.1. NON-INVASIVE CANCER DIAGNOSIS MARKET BY TYPE
4.1.1. BLOOD CANCER
4.1.2. SOLID TUMORS
4.1.3. BREAST CANCER
4.1.4. LUNG CANCER
4.1.5. OTHERS
4.2. NON-INVASIVE CANCER DIAGNOSIS MARKET BY TECHNIQUES
4.2.1. CLINICAL CHEMISTRY
4.2.2. IMMUNOCHEMISTRY/IMMUNOASSAY
4.2.3. MOLECULAR DIAGNOSTICS
4.2.4. OTHER CLINICAL INSTRUMENTS
COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.2. KEY COMPANY ANALYSIS
REGIONAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. UNITED STATES
6.1.2. CANADA
6.1.3. REST OF NORTH AMERICA
6.2. EUROPE
6.2.1. UNITED KINGDOM
6.2.2. FRANCE
6.2.3. GERMANY
6.2.4. ITALY
6.2.5. SPAIN
6.2.6. REST OF EUROPE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.4. REST OF THE WORLD
COMPANY PROFILES
7.1. A&G PHARMACEUTICAL, INC.
7.1.1. INTRODUCTION
7.1.2. A7G PHARMACEUTICAL PRODUCT PORTFOLIO
7.1.3. A&G PHARMACEUTICAL RECENT ACTIVITIES
7.2. ACCELERATE BRAIN CANCER CURE
7.2.1. INTRODUCTION
7.2.2. ACCELERATE BRAIN CANCER CURE PRODUCT PORTFOLIO
7.2.3. ACCELERATE BRAIN CANCER CURE RECENT ACTIVITIES
7.3. ADMERA HEALTH INNOVATIONS
7.3.1. INTRODUCTION
7.3.2. ADMERA HEALTH INNOVATIONS PRODUCT PORTFOLIO
7.3.3. ADMERA HEALTH INNOVATIONS RECENT ACTIVITIES
7.4. AFFYMETRIX INC.
7.4.1. INTRODUCTION
7.4.2. AFFYMETRIX INC. PRODUCT PORTFOLIO
7.4.3. AFFYMETRIX INC. RECENT ACTIVITIES
7.5. AVIVA BIOSCIENCES CORPORATION
7.5.1. INTRODUCTION
7.5.2. AVIVA BIOSCIENCES CORPORATION PRODUCT PORTFOLIO
7.5.3. AVIVA BIOSCIENCES CORPORATION RECENT ACTIVITIES
7.6. BIOVIEW INC.
7.6.1. INTRODUCTION
7.6.2. BIOVIEW INC. PRODUCT PORTFOLIO
7.6.3. BIOVIEW INC. RECENT ACTIVITIES
7.7. CYNVENIO BIOSYSTEMS
7.7.1. INTRODUCTION
7.7.2. CYNVENIO BIOSYSTEMS PRODUCT PORTFOLIO
7.7.3. CYNVENIO BIOSYSTEMS RECENT ACTIVITIES
7.8. DIGENE CORPORATION
7.8.1. INTRODUCTION
7.8.2. DIGENE CORPORATION PRODUCT PORTFOLIO
7.8.3. DIGENE CORPORATION RECENT ACTIVITIES
7.9. EXOSOMICS SIENA
7.9.1. INTRODUCTION
7.9.2. EXOSOMICS SIENA PRODUCT PORTFOLIO
7.9.3. EXOSOMICS SIENA RECENT ACTIVITIES
7.10. FLARITON HEALTH
7.10.1. INTRODUCTION
7.10.2. FLARITON HEALTH PRODUCT PORTFOLIO
7.10.3. FLARITON HEALTH RECENT ACTIVITIES
7.11. GEN-PROBE INCORPORATED
7.11.1. INTRODUCTION
7.11.2. GEN-PROBE INCORPORATED PRODUCT PORTFOLIO
7.11.3. GEN-PROBE INCORPORATED RECENT ACTIVITIES
7.12. IV DIAGNOSTICS, INC.
7.12.1. INTRODUCTION
7.12.2. IV DIAGNOSTICS, INC. PRODUCT PORTFOLIO
7.12.3. IV DIAGNOSTICS, INC. RECENT ACTIVITIES
7.13. LABCORP
7.13.1. INTRODUCTION
7.13.2. LABCORP PRODUCT PORTFOLIO
7.13.3. LABCORP RECENT ACTIVITIES
7.14. NEOGENOMICS
7.14.1. INTRODUCTION
7.14.2. NEOGENOMICS PRODUCT PORTFOLIO
7.14.3. NEOGENOMICS RECENT ACTIVITIES
7.15. NOVARTIS
7.15.1. INTRODUCTION
7.15.2. NOVARTIS PRODUCT PORTFOLIO
7.15.3. NOVARTIS RECENT ACTIVITIES
7.16. NOVIGENIX
7.16.1. INTRODUCTION
7.16.2. NOVIGENIX PRODUCT PORTFOLIO
7.16.3. NOVIGENIX RECENT ACTIVITIES
7.17. PRECISION THERAPEUTICS, INC.
7.17.1. INTRODUCTION
7.17.2. PRECISION THERAPEUTICS, INC.PRODUCT PORTFOLIO
7.17.3. PRECISION THERAPEUTICS, INC. RECENT ACTIVITIES
7.18. QIAGEN
7.18.1. INTRODUCTION
7.18.2. QIAGENPRODUCT PORTFOLIO
7.18.3. QIAGENRECENT ACTIVITIES
7.19. QUANTERIX
7.19.1. INTRODUCTION
7.19.2. QUANTERIX PRODUCT PORTFOLIO
7.19.3. QUANTERIX RECENT ACTIVITIES
7.20. QUEST DIAGNOSTICS INC.,
7.20.1. INTRODUCTION
7.20.2. QUEST DIAGNOSTICS INC., PRODUCT PORTFOLIO
7.20.3. QUEST DIAGNOSTICS INC., RECENT ACTIVITIES
LIST OF TABLES
Table 1 GLOBAL NON-INVASIVE CANCER DIAGNOSIS MARKET RESEARCH AND ANALYSIS BY THERAPEUTICS, 2015-2022 ($ MILLION)
Table 2 GLOBAL BLOOD CANCER MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 3 GLOBAL SOLID TUMORS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 4 GLOBAL BREAST CANCER MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 5 GLOBAL LUNG CANCER MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 6 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 7 GLOBAL NON-INVASIVE CANCER DIAGNOSIS MARKET RESEARCH AND ANALYSIS, BY TECHNIQUE 2015-2022 ($ MILLION)
Table 8 GLOBAL CLINICAL CHEMISTRY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 9 GLOBAL IMMUNOCHEMISTRY/IMMUNOASSAY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 10 GLOBAL MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 11 GLOBAL OTHER CLINICAL INSTRUMENTS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 12 A&G PHARMACEUTICAL, INC. PRODUCT PORTFOLIO
Table 13 A&G PHARMACEUTICAL, INC. RECENT ACTIVITIES
Table 14 ACCELERATE BRAIN CANCER CURE PRODUCT PORTFOLIO
Table 15 ACCELERATE BRAIN CANCER CURE RECENT ACTIVITIES
Table 16 ADMERA HEALTH INNOVATIONS PRODUCT PORTFOLIO
Table 17 ADMERA HEALTH INNOVATIONS RECENT ACTIVITIES
Table 18 AFFYMETRIX INC. PRODUCT PORTFOLIO
Table 19 AFFYMETRIX INC. RECENT ACTIVITIES
Table 20 AVIVA BIOSCIENCES CORPORATION PRODUCT PORTFOLIO
Table 21 AVIVA BIOSCIENCES CORPORATION RECENT ACTIVITIES
Table 22 BIOVIEW INC. PRODUCT PORTFOLIO
Table 23 BIOVIEW INC. RECENT ACTIVITIES
Table 24 CYNVENIO BIOSYSTEMS PRODUCT PORTFOLIO
Table 25 CYNVENIO BIOSYSTEMS RECENT ACTIVITIES
Table 26 DIGENE CORPORATION PRODUCT PORTFOLIO
Table 27 DIGENE CORPORATION RECENT ACTIVITIES
Table 28 EXOSOMICS SIENA PRODUCT PORTFOLIO
Table 29 EXOSOMICS SIENA RECENT ACTIVITIES
Table 30 FLARITON HEALTH PRODUCT PORTFOLIO
Table 31 FLARITON HEALTH RECENT ACTIVITIES
Table 32 GEN-PROBE INCORPORATED PRODUCT PORTFOLIO
Table 33 GEN-PROBE INCORPORATED RECENT ACTIVITIES
Table 34 IVDIAGNOSTICS, INC. PRODUCT PORTFOLIO
Table 35 IVDIAGNOSTICS, INC. RECENT ACTIVITIES
Table 36 LABCORP PRODUCT PORTFOLIO
Table 37 LABCORP RECENT ACTIVITIES
Table 38 NEOGENOMICS PRODUCT PORTFOLIO
Table 39 NEOGENOMICS RECENT ACTIVITIES
Table 40 NOVARTISPRODUCT PORTFOLIO
Table 41 NOVARTISRECENT ACTIVITIES
Table 42 NOVIGENIXPRODUCT PORTFOLIO
Table 43 NOVIGENIXRECENT ACTIVITIES
Table 44 PRECISION THERAPEUTICS, INC.PRODUCT PORTFOLIO
Table 45 PRECISION THERAPEUTICS, INC. RECENT ACTIVITIES
Table 46 QIAGENPRODUCT PORTFOLIO
Table 47 QIAGENRECENT ACTIVITIES
Table 48 QUANTERIX PRODUCT PORTFOLIO
Table 49 QUANTERIX RECENT ACTIVITIES
Table 50 QUEST DIAGNOSTICS INC., PRODUCT PORTFOLIO
Table 51 QUEST DIAGNOSTICS INC., RECENT ACTIVITIES
Table 1 GLOBAL NON-INVASIVE CANCER DIAGNOSIS MARKET RESEARCH AND ANALYSIS BY THERAPEUTICS, 2015-2022 ($ MILLION)
Table 2 GLOBAL BLOOD CANCER MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 3 GLOBAL SOLID TUMORS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 4 GLOBAL BREAST CANCER MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 5 GLOBAL LUNG CANCER MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 6 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 7 GLOBAL NON-INVASIVE CANCER DIAGNOSIS MARKET RESEARCH AND ANALYSIS, BY TECHNIQUE 2015-2022 ($ MILLION)
Table 8 GLOBAL CLINICAL CHEMISTRY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 9 GLOBAL IMMUNOCHEMISTRY/IMMUNOASSAY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 10 GLOBAL MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 11 GLOBAL OTHER CLINICAL INSTRUMENTS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Table 12 A&G PHARMACEUTICAL, INC. PRODUCT PORTFOLIO
Table 13 A&G PHARMACEUTICAL, INC. RECENT ACTIVITIES
Table 14 ACCELERATE BRAIN CANCER CURE PRODUCT PORTFOLIO
Table 15 ACCELERATE BRAIN CANCER CURE RECENT ACTIVITIES
Table 16 ADMERA HEALTH INNOVATIONS PRODUCT PORTFOLIO
Table 17 ADMERA HEALTH INNOVATIONS RECENT ACTIVITIES
Table 18 AFFYMETRIX INC. PRODUCT PORTFOLIO
Table 19 AFFYMETRIX INC. RECENT ACTIVITIES
Table 20 AVIVA BIOSCIENCES CORPORATION PRODUCT PORTFOLIO
Table 21 AVIVA BIOSCIENCES CORPORATION RECENT ACTIVITIES
Table 22 BIOVIEW INC. PRODUCT PORTFOLIO
Table 23 BIOVIEW INC. RECENT ACTIVITIES
Table 24 CYNVENIO BIOSYSTEMS PRODUCT PORTFOLIO
Table 25 CYNVENIO BIOSYSTEMS RECENT ACTIVITIES
Table 26 DIGENE CORPORATION PRODUCT PORTFOLIO
Table 27 DIGENE CORPORATION RECENT ACTIVITIES
Table 28 EXOSOMICS SIENA PRODUCT PORTFOLIO
Table 29 EXOSOMICS SIENA RECENT ACTIVITIES
Table 30 FLARITON HEALTH PRODUCT PORTFOLIO
Table 31 FLARITON HEALTH RECENT ACTIVITIES
Table 32 GEN-PROBE INCORPORATED PRODUCT PORTFOLIO
Table 33 GEN-PROBE INCORPORATED RECENT ACTIVITIES
Table 34 IVDIAGNOSTICS, INC. PRODUCT PORTFOLIO
Table 35 IVDIAGNOSTICS, INC. RECENT ACTIVITIES
Table 36 LABCORP PRODUCT PORTFOLIO
Table 37 LABCORP RECENT ACTIVITIES
Table 38 NEOGENOMICS PRODUCT PORTFOLIO
Table 39 NEOGENOMICS RECENT ACTIVITIES
Table 40 NOVARTISPRODUCT PORTFOLIO
Table 41 NOVARTISRECENT ACTIVITIES
Table 42 NOVIGENIXPRODUCT PORTFOLIO
Table 43 NOVIGENIXRECENT ACTIVITIES
Table 44 PRECISION THERAPEUTICS, INC.PRODUCT PORTFOLIO
Table 45 PRECISION THERAPEUTICS, INC. RECENT ACTIVITIES
Table 46 QIAGENPRODUCT PORTFOLIO
Table 47 QIAGENRECENT ACTIVITIES
Table 48 QUANTERIX PRODUCT PORTFOLIO
Table 49 QUANTERIX RECENT ACTIVITIES
Table 50 QUEST DIAGNOSTICS INC., PRODUCT PORTFOLIO
Table 51 QUEST DIAGNOSTICS INC., RECENT ACTIVITIES
LIST OF FIGURES
Figure 1 NORTH AMERICA MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure 2 US MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure 3 CANADA MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure 4 EUROPEAN MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure 5 UK MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure 6 FRANCE MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure 7 GERMANY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure 8 ITALY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure 9 SPAIN MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure 10 ROE MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure 11 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure 12 INDIA MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure 13 CHINA MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure 14 JAPAN MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure 15 ROPAC MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure 16 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure 1 NORTH AMERICA MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure 2 US MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure 3 CANADA MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure 4 EUROPEAN MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure 5 UK MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure 6 FRANCE MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure 7 GERMANY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure 8 ITALY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure 9 SPAIN MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure 10 ROE MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure 11 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure 12 INDIA MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure 13 CHINA MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure 14 JAPAN MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure 15 ROPAC MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
Figure 16 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2015-2022 ($ MILLION)
